- Bertolin-Boronat, C
- Merenciano-Gonzalez H
- Marcos-Garcés, Víctor
- Martínez-Mas, Maria Luz
- Climent Alberola, Josefa Ines
- Pérez, Nerea
- López-Bueno, Laura
- Esteban-Argente, Maria Concepcion
- Reig, Maria
- Arizon Benito, Ana
- Paya Rubio, Alfonso
- Rios-Navarro, César
- De Dios, Elena
- Gavara-Doñate, Josep|||0000-0002-3483-7066
[EN] Background: Exercise-based cardiac rehabilitation programs (CRP) are recommended for patients following acute coronary syndrome to potentially improve high-density lipoprotein cholesterol (HDL-C) levels and prognosis. However, not all patients reach target HDL-C levels. Here we analyze the dynamics and predictors of HDL-C increase during CRP in patients following ST-segment elevation myocardial infarction or occlusion myocardial infarction. Methods: We conducted a prospective study of myocardial infarction patients who completed exercise-based Phase 2 CRP. Data was collected on clinical variables, cardiovascular risk factors, treatment goals, pharmacological therapy, and health outcomes through questionnaires at the beginning and at the end of Phase 2 CRP. Lipid profile analysis was performed before discharge, 4 to 6 weeks after discharge, and at the end of Phase 2 CRP. Changes in lipid profiles were evaluated, and predictors of failure to increase HDL-C levels were identified by binary logistic regression analysis. Results: Our cohort comprised 121 patients (mean age 61.67 +/- 10.97 years, 86.8% male, and 47.9% smokers before admission). A significant decrease in total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C) were noted, along with an increase in HDL-C (43.87 +/- 9.18 vs. 39.8 +/- 10.03 mg/dL, p < 0.001). Patients achieving normal HDL-C levels (>40 mg/dL in men and >50 mg/dL in women) significantly increased from 34.7% at admission to 52.9% the end of Phase 2. Multivariable analysis revealed smoking history (hazard ratio [HR] = 0.35, 95% confidence interval [CI], 0.11-0.96, p = 0.04), increased reduction in total cholesterol (HR = 0.94, 95% CI, 0.89-0.98, p = 0.004), and increased reduction in LDL-C (HR = 0.94, 95% CI, 0.89-0.99, p = 0.01) were inversely associated with failure to increase HDL-C levels. Conversely, higher HDL-C before CRP (HR = 1.15, 95% CI, 1.07-1.23, p < 0.001) and increased lipoprotein (a) (HR = 1.01, 95% CI, 1-1.02, p = 0.04) predicted failure to increase HDL-C levels. No significant correlations were found with Mediterranean diet adherence, weekly physical activity, training modalities, or physical fitness parameters. Conclusions: Participation in an exercise-based Phase 2 CRP led to mild but significant increases in HDL-C. Smoking history and patients experiencing substantial reductions in total cholesterol and LDL-C were more likely to experience HDL-C increases, unlike those with higher HDL-C and lipoprotein (a) levels before CRP., This research was funded by Instituto de Salud Carlos III, Fondos Europeos de Desarrollo Regional FEDER and Fondo Social Europeo Plus (FSE+) (grant numbers PI20/00637, PI23/01150, CIBERCV16/11/00486, CIBERCV16/11/00420, CIBERCV16/11/00479 and postgraduate contracts CM21/00175 and CM23/00246) and by Conselleria de Educación of the Generalitat Valenciana (PROMETEO/2021/008). Dr. Marcos-Garcés acknowledges funding from the Instituto de Salud Carlos III and co-funding from Fondo Social Europeo Plus (FSE+) (grant number JR23/00032), as well as a GE 2023 grant from the Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital of the Generalitat Valenciana (CIGE/2022/26). Drs. Ríos-Navarro and Gavara acknowledge funding from the Conselleria de Educación Generalitat Valenciana and co-funding from Fondo Social Europeo Plus (grant numbers CIAPOS/2023/247 and CIAPOS2023/248)
Proyecto:
Instituto de Salud Carlos III / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) / PI20/00637
,
Ministerio de Economía y Competitividad / CB16/11/00420
,
Ministerio de Economía y Competitividad / CB16/11/00479
,
Ministerio de Economía y Competitividad / CB16/11/00486
,
Generalitat Valenciana / PROMETEO/2021/008
,
Generalitat Valenciana / CIAPOS/2023/247
,
Generalitat Valenciana / CIGE/2022/26
,
Generalitat Valenciana / CIAPOS2023/248
,
Instituto de Salud Carlos III / CM21/00175
,
Instituto de Salud Carlos III / CM23/00246
,
Instituto de Salud Carlos III / JR23/00032
,
Instituto de Salud Carlos III / PI23/01150